Tempol Moderately Extends Survival in a hSOD1G93A ALS Rat Model by Inhibiting Neuronal Cell Loss, Oxidative Damage and Levels of Non-Native hSOD1G93A Forms

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Linares, Edlaine ^a   Seixas, Luciana V ^a   dos Prazeres, Janaina N ^a   Ladd, Fernando V L ^a   Ladd, Aliny A B L ^a   Coppi, Antonio A ^a   Augusto, Ohara ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; TEMPOL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HSOD1 TRANSGENE; MALE; MUTANT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RAT; SPINAL CORD ATROPHY; SURVIVAL; TRANSGENE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIOXIDANTS; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MOTOR NEURONS; MUTATION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTEIN FOLDING; RATS; RATS, TRANSGENIC; SPIN LABELS; SPINAL CORD; SUPEROXIDE DISMUTASE; SURVIVAL RATE;

EID: 84873553960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055868     Document Type: Article

References (68)

1. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
2. Julien J-P, (2001) Amyotrophic lateral sclerosis: unfolding the toxicity of the misfolded. Cell 104: 581-591.
3. Valentine JS, Doucette PA, Zittin Potter S, (2005) Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Ann Rev Biochem 74: 563-593.
4. Barber SC, Mead RJ, Shaw PJ, (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762: 1051-1067.
5. Boillée S, Cleveland DW, (2008) Revisiting oxidative damage in ALS: microglia, Nox and mutant SOD1. J Clin Inves 118: 474-477.
6. Trumbull KA, Beckman JS, (2009) A role for copper in the toxicity of zinc-deficient superoxide dismutase to motor neurons in amyotrophic lateral sclerosis. Antioxid Redox Signal 11: 1627-1639.
7. Chattopadhyay M, Valentine JS, (2009) Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. Antioxid Redox Signal 11: 1603-1614.
8. Seetharaman SV, Prudencio M, Karch C, Holloway SP, Borchelt DR, et al. (2009) Immature copper-zinc superoxide dismutase and familial amyotrophic lateral sclerosis. Exp Biol Med 234: 1140-1154.
9. Polymenidou M, Cleveland DW, (2011) The seeds of neurodegeneration: Prion-like spreading in ALS. Cell 147: 498-508.
10. Barbeito LH, Pehar M, Cassina P, Vargas MR, Peluffo H, et al. (2004) A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 47: 263-274.
11. Barber SC, Shaw PJ, (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48: 629-641.
12. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644-654.
13. Fitzmaurice PS, Shaw IC, Kleiner HE, Miller RT, Monks TJ, et al. (1996) Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve 19: 797-798.
14. Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326-334.
15. Andrus PK, Fleck TJ, Gurney ME, Hall ED, (1998) Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71: 2041-2048.
16. Barbosa LF, Cerqueira FM, Macedo AF, Garcia CC, Angeli JP, et al. (2010) Increased SOD1 association with chromatin, DNA damage, p53 activation, and apoptosis in a cellular model of SOD1-linked ALS. Biochim Biophys Acta 1802: 462-471.
17. Rao SD, Weiss JH, (2004) Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis. Trends Neurosci 27: 17-23.
18. Trotti D, Rolfs A, Danbolt NC, Brown RH Jr, Hediger MA, (1999) SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter. Nat Neurosci 2: 427-433.
19. Desnuelle C, Dib M, Garrel C, Favier A, (2001) A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2: 9-18.
20. Orrell R, Lane R, Ross M, (2007) Antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev pp. CD002829.
21. Benatar M, (2007) Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 26: 1-13.
22. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 11: 38-45.
23. Jucker M, (2010) The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 16: 1210-1214.
24. Mead RJ, Bennett EJ, Kennerley AJ, Sharp P, Sunyach C, et al. (2011) Optimised and rapid pre-clinical screening in the SOD1(G93A) transgenic mouse model of amyotrophic lateral sclerosis (ALS). PLoS One 6: e23244.
25. Thiemermann C, (2003) Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. Crit Care Med 31: S76-S84.
26. Soule BP, Hyodo F, Matsumoto K, Simone NL, Cook JA, et al. (2007) The chemistry and biology of nitroxide compounds. Free Radic Biol Med 42: 1632-1650.
27. Augusto O, Trindade DF, Linares E, Vaz SM, (2008) Cyclic nitroxides inhibit the toxicity of nitric oxide-derived oxidants: mechanisms and implications. An Acad Bras Cienc 80: 179-189.
28. Wilcox CS, Pearlman A, (2008) Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol Rev 60: 418-469.
29. Tsuhako MH, Augusto O, Linares E, Chadi G, Giorgio S, et al. (2010) Tempol ameliorates murine viral encephalomyelitis by preserving the blood-brain barrier, reducing viral load, and lessening inflammation. Free Radic Biol Med 48: 704-712.
30. Wilcox CS, Pearlman A, (2010) Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Therapeut 126: 119-145.
31. Matsumoto A, Okada Y, Nakamichi M, Nakamura M, Toyama Y, et al. (2006) Disease progression of human SOD (G93A) transgenic ALS model. J Neurosc Res 83: 119-133.
32. Samuni A, Goldstein S, Russo A, Mitchell JB, Krishna MC, et al. (2002) Kinetics and mechanism of hydroxyl radical and OH-adduct radical reactions with nitroxides and with their hydroxylamines. J Am Chem Soc 124: 8719-8724.
33. Howland DS, Liu J, She Y, Goad B, Maragakis NJ, et al. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 99: 1604-1609.
34. Linares E, Giorgio S, Augusto O, (2008) Inhibition of in vivo leishmanicidal mechanisms by tempol: Nitric oxide down-regulation and oxidant scavenging. Free Radic Biol Med 44: 1668-1676.
35. Ladd AL, Ladd FVL, Silva AAP, Oliveira MF, Souza RR, et al. (2012) SCG postnatal remodeling - hypertrophy and neuron number stability - in Spix's Yellow-toothed Cavies (Galea spixii). Int J Dev Neurosci 30: 129-137.
36. Steele C, Fioretto ET, Sasahara TH, Guidi WL, Lima AR, et al. (2006) On the atrophy of the internal carotid artery in capybara. Cell Tissue Res 326: 737-748.
37. Gundersen HJG, Jensen FB, Kieu K, Nielsen J, (1999) The efficiency of systematic sampling in stereology-reconsidered. J Microsc 193: 199-211.
38. Howard CV, Reed MG (2010) Unbiased stereology. Three-dimensional measurement in microscopy. Liverpool: QTP Publications.
39. Gundersen HJG, Bagger P, Bendtsen TF, (1988) The new stereoloical tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96: 857-881.
40. Gundersen HJG, (2002) The smooth fractionator. J Microsc 207: 191-210.
41. Gundersen HJG, (1977) Notes of the estimation of the numerical density of arbitrary profiles: the edge effect. J Microsc 111: 219-223.
42. Vedel Jensen EB, Gundersen HJG, (1993) The rotator. J Microsc 170: 35-44.
43. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, et al. (1999) Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic Biol Med 26: 1231-1237.
44. Wang P, Powell SR, (2010) Decreased sensitivity associated with an altered formulation of a commercially available kit for detection of protein carbonyls. Free Radic Biol Med 49: 119-121.
45. Johnston JA, Dalton MJ, Gurney ME, Kopito RR, (2000) Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 97: 12571-12576.
46. Gruzman A, Wood WL, Alpert E, Prasad MD, Miller RG, et al. (2007) Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 104: 12524-12529.
47. Shaw BF, Valentine JS, (2007) How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem Sci 32: 78-85.
48. Medinas DB, Gozzo FC, Santos LF, Iglesias AH, Augusto O, (2010) A ditryptophan cross-link is responsible for the covalent dimerization of human superoxide dismutase 1 during its bicarbonate-dependent peroxidase activity. Free Radic Biol Med 49: 1046-1053.
49. Rakhit R, Robertson J, Vande Velde C, Horne P, Ruth DM, et al. (2007) An immunological epitope selective for pathological monomer-misfolded SOD1 in ALS. Nat Med 13: 754-759.
50. Kerman A, Liu HN, Croul S, Bilbao J, Rogaeva E, et al. (2010) Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol 119: 335-344.
51. Mitchell JB, Xavier S, DeLuca AM, Sowers AL, Cook JA, et al. (2003) A low molecular weight antioxidant decreases weight and lowers tumor incidence. Free Radic Biol Med 34: 93-102.
52. Schubert R, Erker L, Barlow C, Yakushiji H, Larson D, et al. (2004) Cancer chemoprevention by the antioxidant tempol in Atm-deficient mice. Hum Mol Genet 13: 1793-1802.
53. Mehlhorn RJ, (1991) Ascorbate- and dehydroascorbic acid-mediated reduction of free radicals in the human erythrocyte. J Biol Chem 266: 2724-2731.
54. Vasquez-Vivar J, Santos AM, Junqueira VBC, Augusto O, (1996) Peroxynitrite-mediated formation of free radicals in human plasma. EPR detection of ascorbyl, albumin-thiyl and uric acid-derived free radicals. Biochem J 314: 869-876.
55. Samuni Y, Gamson J, Samuni A, Yamada K, Russo A, et al. (2004) Factors influencing nitroxide reduction and cytoxicity in vitro. Antioxid Redox Signal 6: 587-595.
56. Urushitani M, Kurisu J, Tsukita K, Takahashi R, (2002) Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. J Neurochem 83: 1030-1042.
57. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, et al. (2005) Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice- A model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 39: 453-462.
58. Nyström T, (2005) Role of oxidative carbonylation in protein quality control and senescence. EMBO J 24: 1311-1317.
59. Chaudhuri AR, de Waal EM, Pierce A, Van Remmen H, Ward WF, et al. (2006) Detection of protein carbonyls in aging liver tissue: A fluorescence-based proteomic approach. Mech Ageing Dev 127: 849-861.
60. Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, et al. (2012) An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci USA 109: 5074-5079.
61. Winterbourn CC, (2008) Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 4: 278-286.
62. Jones DP, Go YM, (2010) Redox compartmentalization and cellular stress. Diabetes Obes Metab 2: 116-125.
63. Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, et al. (2010) Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 11: 1396-1403.
64. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, et al. (2010) Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS One 5: e11552.
65. Hahn SM, Sullivan FJ, DeLuca AM, Bacher JD, Liebmann J, et al. (1999) Hemodynamic effect of the nitroxide superoxide dismutase mimics. Free Radic Biol Med 27: 529-535.
66. Urushitani M, Ezzi SA, Julien JP, (2007) Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 104: 2495-2500.
67. Takeuchi S, Fujiwara N, Ido A, Oono M, Takeuchi Y, et al. (2010) Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice. J Neuropathol Exp Neurol 69: 1044-1056.
68. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, et al. (2004) Monomeric Cu,Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 279: 15499-15504.